Aclaris Therapeutics (NASDAQ:ACRS) Lifted to “Hold” at ValuEngine

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

ACRS has been the topic of a number of other research reports. Leerink Swann lowered Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 27th. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 8th. Cantor Fitzgerald reduced their price target on Aclaris Therapeutics from $50.00 to $24.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 12th. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, Svb Leerink downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $19.69.

ACRS stock traded down $0.07 during mid-day trading on Thursday, reaching $1.21. The company had a trading volume of 1,887,300 shares, compared to its average volume of 632,610. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.33 and a quick ratio of 4.30. The company has a market cap of $71.40 million, a P/E ratio of -0.30 and a beta of 0.77. The company has a fifty day moving average of $2.80. Aclaris Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $18.98.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.05). The company had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. Sell-side analysts predict that Aclaris Therapeutics will post -2.87 EPS for the current year.

In other news, major shareholder James E. Flynn sold 699,475 shares of the stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $2.69, for a total value of $1,881,587.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder James E. Flynn sold 454,261 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $4.59, for a total value of $2,085,057.99. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,107,983 shares of company stock worth $9,303,479. Company insiders own 14.80% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new position in Aclaris Therapeutics during the 4th quarter worth approximately $778,000. American International Group Inc. grew its stake in Aclaris Therapeutics by 31.4% during the 4th quarter. American International Group Inc. now owns 23,307 shares of the biotechnology company’s stock worth $172,000 after buying an additional 5,575 shares during the last quarter. Geode Capital Management LLC grew its stake in Aclaris Therapeutics by 38.4% during the 4th quarter. Geode Capital Management LLC now owns 380,007 shares of the biotechnology company’s stock worth $2,808,000 after buying an additional 105,361 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Aclaris Therapeutics by 105.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 489,516 shares of the biotechnology company’s stock worth $3,618,000 after buying an additional 250,963 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Aclaris Therapeutics by 25.6% during the 4th quarter. Northern Trust Corp now owns 444,942 shares of the biotechnology company’s stock worth $3,288,000 after buying an additional 90,791 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Read More: How Do Tariffs Affect Trade Balances?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.